Recro Pharma

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. Our lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo controlled trial demonstrating pain relief. We have studied various dosage forms of Dex in eight completed clinical studies, two of which were placebo controlled trials that demonstrated meaningful pain relief. As our product candidates are not opioid based drugs, we expect to overcome many of the side effects associated with commonly prescribed opioid based therapeutics, including addiction, constipation and respiratory distress while maintaining analgesic, or pain relieving, effect. We are ready to begin a Phase IIb trial with Dex in patients experiencing post-operative pain. We believe Dex will become an alternative pain medication to opioids for the more than 50 million surgical procedures that require post-operative pain medication. If approved, Dex would also be the first and only approved post-operative pain drug in its class of drugs.
Company Growth (employees)
Malvern, US
Size (employees)
195 (est)+5%
Recro Pharma is headquartered in Malvern, US

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd

Recro Pharma Financials and Metrics

Recro Pharma Financials

Recro Pharma's revenue was reported to be $18.7 m in Q1, 2017

Revenue (Q1, 2017)

18.7 m

Gross profit (Q1, 2017)

8.2 m

Gross profit margin (Q1, 2017), %


Net income (Q1, 2017)

(8.1 m)

EBIT (Q1, 2017)

(7.3 m)

Market capitalization (20-Oct-2017)

172.4 m

Cash (31-Mar-2017)

19.5 m
Recro Pharma's current market capitalization is $172.4 m.
USDFY, 2014FY, 2015FY, 2016


52 m69.3 m

Revenue growth, %


Cost of goods sold

28.1 m37.2 m

Gross profit

23.9 m32.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


18.7 m16.5 m17.7 m17.3 m17 m18.7 m

Cost of goods sold

9.4 m10 m10.3 m9.5 m5.7 m10.5 m

Gross profit

9.3 m6.5 m7.5 m7.7 m11.2 m8.2 m

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016


19.7 m19.8 m64.5 m

Accounts Receivable

89.6 k8.6 m10.4 m


9 m1.1 m

Current Assets

20.4 m38.7 m84.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


27.8 m23.9 m16.6 m15.7 m28.3 m14.9 m14.8 m24.8 m19.5 m

Accounts Receivable

86.8 k80.2 k15 m9.6 m12.2 m11.5 m12.4 m12.3 m


9.6 m8.6 m7.6 m6.7 m9.8 m7.8 m

Current Assets

28.1 m24.1 m17.3 m42.4 m48.4 m36.2 m35.2 m49 m77.3 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(16.1 m)3 m(30.2 m)

Depreciation and Amortization

1.4 k4.1 m5 m

Accounts Receivable

(51.2 k)4 m(1.8 m)


1.3 m(325 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.9 m)(12.7 m)(4.1 m)(5.5 m)(7.6 m)(6.5 m)(14.4 m)(19.8 m)(8.1 m)

Depreciation and Amortization

1.3 m2.7 m1.3 m2.5 m3.8 m1.2 m

Accounts Receivable

38.4 k(48.4 k)9.4 k(1.9 m)


345 k1.4 m1.3 m2.3 m(830 k)936 k
USDY, 2017


98.4 k

Financial Leverage

2.7 x
Show all financial metrics

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

Show all operating metrics

Recro Pharma Market Value History

Recro Pharma Revenue Breakdown

Traffic Overview of Recro Pharma

Recro Pharma Company Life and Culture

You may also be interested in